Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Wolfgang Miesbach: How a ‘Non‑Bleeding’ Factor XII Shapes Thrombosis and Fibrinolysis
Wolfgang Miesbach,Mariantonietta Tripodo/LinkedIn
May 4, 2026, 06:10

Wolfgang Miesbach: How a ‘Non‑Bleeding’ Factor XII Shapes Thrombosis and Fibrinolysis

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:

”The Secret Life of FXII: How a ‘Non‑Bleeding’ Factor Shapes Thrombosis and Fibrinolysis.

In her excellent talk at the EHA‑SWG Scientific Meeting on Bleeding and Platelet Disorders, Mariantonietta Tripodo addressed a fascinating question: ‘Can dual targeting of FXII and Gas6 prevent thrombosis with no risk of bleeding?’

FXII has long been viewed as dispensable for normal hemostasis because congenital FXII deficiency does not cause a bleeding phenotype.

  • New data show that FXIIa actively shapes fibrin structure and promotes fibrinolysis, influencing how stable a clot is and how quickly it is broken down.
  • Gas6, in turn, acts mainly at the platelet–vessel wall interface: it amplifies platelet activation and supports platelet adhesion and aggregation via TAM receptors, adding another layer of control over thrombus formation that is partly independent of classical coagulation.
  • In experimental models, lack or inhibition of FXII and Gas6 reduces thrombosis and appears to spare primary hemostasis – but it also modifies fibrinolytic activity, with hints of hyperfibrinolysis when both pathways are absent.

So, the supposed ‘silent’ FXII is revealing a much more nuanced role: not a classic bleeding factor, but a regulator of clot architecture and lysis – and, together with Gas6, a highly attractive yet complex target for safer antithrombotic strategies.

I am very curious to see how these mechanistic insights will translate into future clinical trials of FXII/Gas6‑directed therapies, especially in patients where conventional anticoagulation is limited by bleeding risk.”

Wolfgang Miesbach: How a ‘Non‑Bleeding’ Factor XII Shapes Thrombosis and Fibrinolysis

Stay updated with Hemostasis Today.

bleeding disorders EHA fibrinolysis FXII Gas6 Health Hematology Hemostasis Hemostasis News Hemostasis Today Mariantonietta Tripodo Medicine Platelet disorders thrombosis Wolfgang Miesbach
NewsFeed